EyeDura Therapeutics Wins Top Industry Honors as Its Sustained-Release Eye Drop Technology Gains Momentum in Ophthalmology Innovation EyeDura Therapeutics Inc., a trailblazing developer of preservative-free, sustained-release ophthalmic therapies, has garnered prominent recognition across two of the ophthalmology industry’s most respected…
Acadia Pharmaceuticals Unveils Ambitious Growth Strategy, Eyes $12 Billion Pipeline with Female-Led R&D Powerhouse More than three decades after its founding in 1993, Acadia Pharmaceuticals is embracing a bold new chapter, unveiling what it calls a biotech transformation under the…
Takeda’s Oveporexton Achieves Landmark Phase 3 Success in Narcolepsy Type 1, Paving Way for First-in-Class Orexin Therapy Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced a major milestone in its development pipeline, revealing that its investigational oral therapy oveporexton (TAK-861) has…
ICON Celebrated for Clinical Research Leadership, Innovation, and Sustainability in 2025 a global leader in healthcare intelligence and clinical research, has received widespread industry recognition during the first half of 2025. The company has been honored with multiple awards acknowledging…
Gamma Delta T Cell Therapy: A Transformative Frontier in Cancer Immunotherapy with U.S. and China Leading Global Trials Gamma delta (γδ) T cell therapy is rapidly emerging as a promising frontier in the field of cancer immunotherapy. Unlike the more…
Manitoba Bioscience Association Backs Government Plan to Boost Research and Clinical Trials Bioscience Association Manitoba (BAM) has voiced strong support for a major new initiative from the Manitoba government aimed at advancing health research and clinical trials across the province.…
Health Secretary Robert F. Kennedy Jr. Endorses Broader RSV Vaccine Use, Following Guidance from Former ACIP Panel Despite ousting the Centers for Disease Control and Prevention’s (CDC) vaccine advisory panel last month, Health and Human Services (HHS) Secretary Robert F.…
Dyadic International Rebrands as Dyadic Applied BioSolutions, Marking Strategic Shift Toward Commercial Bioprocessing Solutions Dyadic International, Inc. (Nasdaq: DYAI), a global biotechnology company known for its proprietary gene expression platforms, has announced a strategic rebrand that reflects its evolution from…
Experimental Drug AC102 Significantly Reverses Tinnitus and Repairs Auditory Damage in Preclinical Study A groundbreaking preclinical study has shown that a single dose of the novel compound AC102 can nearly eliminate tinnitus symptoms while also repairing critical damage in the…
Pneumagen Publishes Promising Phase II Results of Neumifil in Peer-Reviewed Journal, Demonstrating Potential as Broad-Spectrum Antiviral for Respiratory Infections Pneumagen, a clinical-stage biotechnology company focused on developing broad-spectrum antivirals, announced the peer-reviewed publication of its positive Phase II clinical trial…
BriaCell Expands Phase 3 Breast Cancer Trial to Major U.S. Centers, Targets Enrollment Completion by 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT), a clinical-stage biotechnology company pioneering targeted immunotherapies for advanced cancer, has announced the expansion of…
JCR Pharmaceuticals Completes Enrollment in Global Phase III Trial for JR-141 Targeting Hunter Syndrome JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) has announced the successful completion of participant enrollment for its global Phase III clinical trial of JR-141 (pabinafusp alfa),…